Market revenue in 2024 | USD 71.6 million |
Market revenue in 2030 | USD 142.5 million |
Growth rate | 12.1% (CAGR from 2025 to 2030) |
Largest segment | Exocrine |
Fastest growing segment | Endocrine |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Exocrine, Endocrine |
Key market players worldwide | Accuray Inc, AstraZeneca PLC ADR, Novartis AG ADR, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Ipsen Pharma, Eli Lilly and Co, Siemens Healthineers AG ADR, Elekta AB ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer treatment market will help companies and investors design strategic landscapes.
Exocrine was the largest segment with a revenue share of 88.41% in 2024. Horizon Databook has segmented the Brazil pancreatic cancer treatment market based on exocrine, endocrine covering the revenue growth of each sub-segment from 2018 to 2030.
The pancreatic cancer treatment market in Brazil is evolving due to the rising incidence of the disease and advancements in treatment modalities. According to WHO, in 2022, Brazil reported around 14,670 cases of pancreatic cancer, which has been steadily increasing due to an aging population and better diagnostic capabilities.
As a result, pharmaceutical companies such as AstraZeneca, Novartis AG, and Bristol-Myers Squibb Company are focusing on expanding their presence in the Brazilian market. AstraZeneca, for instance, has seen a significant uptick in clinical trial participation.
With its PD-L1 inhibitor showing promising results in early-stage trials across several Brazilian cities. These therapies have gained traction in leading Brazilian oncology centers, where genetic profiling and molecular treatments are becoming more commonplace, allowing for tailored approaches that address the specific needs of pancreatic cancer patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil pancreatic cancer treatment market , including forecasts for subscribers. This country databook contains high-level insights into Brazil pancreatic cancer treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account